These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2377 related articles for article (PubMed ID: 23470321)

  • 21. Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies.
    Dobrin A; Lindenbergh PL; Shi Y; Perica K; Xie H; Jain N; Chow A; Wolchok JD; Merghoub T; Sadelain M; Hamieh M
    Nat Cancer; 2024 May; 5(5):760-773. PubMed ID: 38503896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The CD28/B7 pathway: a novel regulator of plasma cell function.
    Njau MN; Jacob J
    Adv Exp Med Biol; 2013; 785():67-75. PubMed ID: 23456839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of CTLA-4 in the regulation and initiation of T-cell responses.
    Chambers CA; Krummel MF; Boitel B; Hurwitz A; Sullivan TJ; Fournier S; Cassell D; Brunner M; Allison JP
    Immunol Rev; 1996 Oct; 153():27-46. PubMed ID: 9010718
    [No Abstract]   [Full Text] [Related]  

  • 24. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28.
    Fallarino F; Fields PE; Gajewski TF
    J Exp Med; 1998 Jul; 188(1):205-10. PubMed ID: 9653097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1 Primarily Targets TCR Signal in the Inhibition of Functional T Cell Activation.
    Mizuno R; Sugiura D; Shimizu K; Maruhashi T; Watada M; Okazaki IM; Okazaki T
    Front Immunol; 2019; 10():630. PubMed ID: 31001256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy.
    Podojil JR; Miller SD
    Immunol Rev; 2009 May; 229(1):337-55. PubMed ID: 19426232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Collaboration of TCR-, CD4- and CD28-mediated signalling in antigen-specific MHC class II-restricted T-cells.
    Gogolák P; Réthy B; Horváth A; Tóth GK; Cervenák L; László G; Rajnavölgyi E
    Immunol Lett; 1996 Dec; 54(2-3):135-44. PubMed ID: 9052868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ups and downs of T cell costimulation.
    Jenkins MK
    Immunity; 1994 Sep; 1(6):443-6. PubMed ID: 7534615
    [No Abstract]   [Full Text] [Related]  

  • 29. Co-stimulation in T cell responses.
    Chambers CA; Allison JP
    Curr Opin Immunol; 1997 Jun; 9(3):396-404. PubMed ID: 9203422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The CD28-B7 Family of Co-signaling Molecules.
    Nagai S; Azuma M
    Adv Exp Med Biol; 2019; 1189():25-51. PubMed ID: 31758530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells.
    Altvater B; Pscherer S; Landmeier S; Niggemeier V; Juergens H; Vormoor J; Rossig C
    Clin Exp Immunol; 2006 Jun; 144(3):447-57. PubMed ID: 16734614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes.
    Keir ME; Latchman YE; Freeman GJ; Sharpe AH
    J Immunol; 2005 Dec; 175(11):7372-9. PubMed ID: 16301644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets.
    Gizinski AM; Fox DA; Sarkar S
    Best Pract Res Clin Rheumatol; 2010 Aug; 24(4):463-77. PubMed ID: 20732645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function.
    Hathcock KS; Laszlo G; Pucillo C; Linsley P; Hodes RJ
    J Exp Med; 1994 Aug; 180(2):631-40. PubMed ID: 7519245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD28-B7 interactions in T-cell activation.
    Allison JP
    Curr Opin Immunol; 1994 Jun; 6(3):414-9. PubMed ID: 7522466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Negative regulation of TCR signaling by linker for activation of X cells via phosphotyrosine-dependent and -independent mechanisms.
    Shapiro MJ; Nguyen CT; Aghajanian H; Zhang W; Shapiro VS
    J Immunol; 2008 Nov; 181(10):7055-61. PubMed ID: 18981125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T-cell co-signalling molecules in graft-versus-host disease.
    Tanaka J; Asaka M; Imamura M
    Ann Hematol; 2000 Jun; 79(6):283-90. PubMed ID: 10901605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4.
    Qureshi OS; Zheng Y; Nakamura K; Attridge K; Manzotti C; Schmidt EM; Baker J; Jeffery LE; Kaur S; Briggs Z; Hou TZ; Futter CE; Anderson G; Walker LS; Sansom DM
    Science; 2011 Apr; 332(6029):600-3. PubMed ID: 21474713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The kinase PDK1 integrates T cell antigen receptor and CD28 coreceptor signaling to induce NF-kappaB and activate T cells.
    Park SG; Schulze-Luehrman J; Hayden MS; Hashimoto N; Ogawa W; Kasuga M; Ghosh S
    Nat Immunol; 2009 Feb; 10(2):158-66. PubMed ID: 19122654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling.
    Rieder SA; Wang J; White N; Qadri A; Menard C; Stephens G; Karnell JL; Rudd CE; Kolbeck R
    Cell Mol Immunol; 2021 Jun; 18(6):1503-1511. PubMed ID: 32005952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 119.